NewAmsterdam Pharma Company N.V (NAMS) Stock News

NewAmsterdam Pharma (NAMS) announced positive topline data from their Phase 3 BROADWAY trial's Alzheimer's Disease sub-study for obicetrapib. The study demonstrated statistically significant reductions in Alzheimer's disease biomarkers, particularly p-tau217, in both the general population (p<0.002) and ApoE4 carriers (p=0.0215) over 12 months. The sub-study included 1,727 patients, with 367 ApoE4 carriers. The BROADWAY trial primarily evaluated obicetrapib's effectiveness in lowering LDL-C in patients with ASCVD and/or HeFH. The study involved 2,530 patients randomized 2:1 to receive 10mg obicetrapib or placebo. A separate Phase 2a trial in early AD patients showed reductions in cholesterol markers in plasma and cerebrospinal fluid, with favorable safety results.

NewAmsterdam Pharma (NAMS), a clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease patients with high LDL-C levels, has announced an R&D Day event scheduled for June 11, 2025, at 9:00 a.m. ET in New York City. The event will feature presentations from key management team members including CEO Michael Davidson, Founder and CSO John Kastelein, CCO BJ Jones, CFO Ian Somaiya, and EVP Matthew Philippe. Investors and analysts can attend either in person (with required pre-registration) or virtually through a live webcast. The presentation materials will be available on the company's investor relations website, with an archived replay accessible after the event.

NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage biopharma company developing oral, non-statin medicines for cardiovascular disease patients, announced its participation in three major investor conferences in June 2025:

1. William Blair Growth Stock Conference (Chicago) - June 3, featuring CEO Michael Davidson presenting a corporate overview at 3:20 PM CT

2. Jefferies Global Healthcare Conference (New York) - June 4, with CFO Ian Somaiya in a fireside chat at 10:30 AM ET

3. Goldman Sachs Healthcare Conference (Miami) - June 9, featuring CEO Michael Davidson and EVP Matthew Phillipe in a fireside chat at 2:40 PM ET

Live webcasts will be available through NewAmsterdam's investor relations website, with archived replays accessible afterward.

NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease patients with elevated LDL-C, has announced its participation in the 2025 RBCCM Global Healthcare Conference. Ian Somaiya, the company's Chief Financial Officer, will engage in a fireside chat on Tuesday, May 20, 2025, at 10:00 a.m. ET. The presentation will be accessible via live webcast through NewAmsterdam's investor relations website, with an archived replay available afterward.

NewAmsterdam Pharma (NAMS) reported Q1 2025 financial results and corporate updates. The company ended Q1 with $808.5 million in cash and equivalents, down from $834.2 million in Q4 2024. Q1 revenue was $3.0 million, up from $1.4 million year-over-year, while net loss improved to $39.5 million from $93.8 million. R&D expenses increased to $44.8 million, and SG&A expenses rose to $27.2 million. The company's lead drug candidate obicetrapib, an oral CETP inhibitor for LDL-C reduction, saw positive developments with data presented at EAS and published in prestigious journals. Key ongoing trials include the PREVAIL Phase 3 CVOT with over 9,500 patients, VINCENT Phase 2 for Lp(a), and REMBRANDT Phase 3 for coronary plaque evaluation. Partner Menarini plans EMA submission in 2H25.

NewAmsterdam Pharma (NAMS) announced groundbreaking results from their BROADWAY and TANDEM Phase 3 studies of obicetrapib, published in The New England Journal of Medicine and The Lancet. The studies demonstrated that obicetrapib, when used with statins, reduced LDL-C by 50% in combination with ezetimibe and 35% as monotherapy. Key findings include a 21% reduction in major adverse cardiovascular events and a 45% reduction in Lp(a) levels across multiple trials. The TANDEM trial showed that over 60% of patients achieved LDL-C reductions greater than 50%, with 70% reaching levels below 55 mg/dL. Phase 2 data revealed that obicetrapib combined with moderate-dose statins reduced LDL-C by approximately 70%. The drug demonstrated a favorable safety profile comparable to placebo across all trials.

NewAmsterdam Pharma (NAMS) has granted inducement share options to eleven new non-executive employees. The grant, approved by the Company's Compensation Committee, covers 197,000 ordinary shares under the 2024 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4).

The share options have an exercise price of $20.03, matching the closing price of NAMS shares on May 1, 2025. The options will vest over a four-year period, with 25% vesting after one year and the remaining 75% vesting in 36 monthly installments, contingent on continued employment.

NewAmsterdam Pharma will present new clinical and preclinical data for its drug obicetrapib at the 93rd European Atherosclerosis Society Congress in Glasgow. The presentations include results from the BROADWAY and TANDEM Phase 3 trials, focusing on the drug's effectiveness in treating hypercholesterolemia.

Key presentations will highlight the fixed-dose combination of obicetrapib with ezetimibe for LDL-C reduction and the drug's safety profile in high cardiovascular risk patients. Additional sessions will cover obicetrapib's impact on atherosclerosis, vascular inflammation, and its effects when combined with moderate-dose statins.

The congress, scheduled for May 4-7, 2025, will feature multiple presentations across different sessions, including late-breaker oral presentations, poster networking sessions, and workshops. The research demonstrates obicetrapib's potential as a novel, oral, low-dose therapy for patients with elevated LDL-C who don't respond well to existing treatments.

NewAmsterdam Pharma (Nasdaq: NAMS) has appointed Adele Gulfo as an independent director to its Board of Directors. Gulfo brings over three decades of healthcare industry experience, notably in launching blockbuster medicines including LIPITOR® and CRESTOR®.

The appointment comes as NewAmsterdam prepares for the potential launch of obicetrapib next year. Gulfo most recently served as CEO for Sumitomo Pharma America's Biopharma Commercial Unit, overseeing commercial and development portfolios across multiple therapeutic areas. Her previous roles include executive positions at Sumitovant Biopharma, Roivant Sciences, Pfizer (where she led the $12 billion U.S. primary care business), and AstraZeneca.

NewAmsterdam is developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C. The company has recently reported positive readouts from three pivotal Phase 3 clinical trials.